Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
449 studies found for:    Open Studies | "Multiple Myeloma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Multiple Myeloma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
2 Recruiting Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
Condition: Multiple Myeloma
Intervention: Biological: CART-138 cells
3 Recruiting Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Bendamustine
4 Recruiting Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
5 Recruiting Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
6 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Recruiting A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Melflufen;   Drug: Dexamethasone
8 Recruiting Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine, Bortezomib, Prednisone
9 Recruiting High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BeEAM
10 Recruiting A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: AMG 224
11 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Fludarabine monophosphate, melphalan, Bortezomib
12 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
13 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
14 Recruiting A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: PAD;   Drug: VCD;   Other: ASCT
15 Recruiting Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib
16 Not yet recruiting Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Condition: Smoldering Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
17 Recruiting Autologous Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
18 Recruiting A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD);   Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab;   Drug: Daratumumab
19 Recruiting Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Daratumumab
20 Not yet recruiting A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Condition: Multiple Myeloma
Intervention: Drug: Denosumab Q4W

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.